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Abstract
Intratumor heterogeneity caused by genetic, phenotypic or functional differences
between cancer cell subpopulations is a considerable clinical challenge.
Understanding subpopulation dynamics is therefore central for both optimization of
existing therapy and for development of new treatment. The aim of this study was to
isolate subpopulations from a primary tumor and by comparing molecular
characteristics of these subpopulations, find explanations to their differing
tumorigenicity. Cell subpopulations from two patient derived in vivo models of
primary breast cancer, ER+ and ER-, were identified. EpCAM+ cells from the ER+
model gave rise to tumors independently of stroma cell support. The tumorigenic
fraction was further divided based on SSEA-4 and CD24 expression. Both markers
were expressed in ER+ breast cancer biopsies. FAC-sorted cells based on EpCAM,
SSEA-4 and CD24 expression were subsequently tested for differences in
functionality by in vivo tumorigenicity assay. Three out of four subpopulations of
cells were tumorigenic and showed variable ability to recapitulate the marker
expression of the original tumor. Whole genome expression analysis of the sorted
populations disclosed high similarity in the transcriptional profiles between the
tumorigenic populations. Comparing the non-tumorigenic vs the tumorigenic
populations, 44 transcripts were, however, significantly differentially expressed.
A subset of these, 26 identified and named genes, highly expressed in the
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non-tumorigenic population, predicted longer overall survival (N5737, p,0.0001)
and distant metastasis free survival (DMFS) (N51379, p,0.0001) when performing
Kaplan-Meier survival analysis using the GOBO online database. The 26 gene set
correlated with longer DMFS in multiple breast cancer subgroups. Copy number
profiling revealed no aberrations that could explain the observed differences in
tumorigenicity. This study emphasizes the functional variability among cell
populations that are otherwise genomically similar, and that the risk of breast
cancer recurrence can only be eliminated if the tumorigenic abilities in multiple
cancer cell subpopulations are inhibited.
Introduction
Cancer cells evading the administered treatment represent the major challenge in
oncology. To understand how some cancer cells are able to escape and cause
recurrence, researchers have compared primary tumors to small ecosystems where
the extracellular components determine the physical environment, and all cell
populations, both normal and neoplastic, represent the diversity of the species
within the system [1, 2]. Large intratumoral cellular diversity ensures that at least
one tumor cell subpopulation is able to tolerate the altered conditions, during
treatment, or relocation to a metastatic site [2, 3]. Our challenge is to understand
why heterogeneity is sustained in the developing tumor, and how to best eradicate
dynamically changing cancer cell populations before they develop strategies to
withstand attacks from various treatment. Details of cancer cell population
dynamics is obviously not possible to study in tissue derived directly from
patients. The best option is therefore, clinically representative patient derived
xenograft models (PDX), that has not been subjected to in vitro culture
differentiation or selection [4]. Such models provide stable access to primary
tumor material enabling repeated experiments on the same primary tumor, and
thus broad characterization of tumor cell subpopulations. PDX stably recapitulate
the molecular composition and the heterogeneity of the mother tumor [4, 5, 6].
The luminal-like PDX used in this study is unique in that it recapitulates estrogen
dependency for growth [7, 8].
Although intratumor heterogeneity is well established, its origin has been
heavily debated. The clonal evolution model was counteracted by the theory of
‘‘cancer stem cells’’ or tumor initiating cells, TICs. Several studies in cell lines [9]
and animal models [10, 11] have indeed indicated the existence of tumor cell
subpopulations with enhanced tumorigenic capacity, compared to the ‘‘bulk’’
tumor cells. Regardless of the origin of TIC populations, identification and
functional characterization of both TICs and the seemingly less tumorigenic
subpopulations are essential for development of more efficient anti-cancer
therapies. It is important to consider that within the ecosystem of a tumor, the
TICs and the apparently less tumorigenic cancer cell populations might in fact be
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equally dependent on each other [12]. Less tumorigenic populations might
constitute a reservoir for development of treatment resistance. Clarification of the
reciprocal relationships between cell populations within breast tumors, and the
dynamics of their differentiation, is therefore needed. The aim of this study was to
find phenotypically different subpopulations within a primary tumor that could
initiate tumor growth independently of each other, and by comparing molecular
characteristics of these subpopulations, find explanations to their diverging
capacity. Another objective was to acquire detailed knowledge on functional
differences, cell surface marker expression, and molecular portraits of tumorigenic
subpopulations within a primary breast cancer model, to open the possibility for
future, controlled studies of cancer cell population dynamics and cellular plasticity
in response to changing conditions. In the present manuscript, subpopulations
from two uniquely well characterized PDX models [7, 8, 13, 14, 15, 16] were
therefore defined, and their cellular surface marker composition was elucidated.
To prospectively characterize the intratumoral heterogeneity; flow cytometry was
combined with in vivo tumorigenicity assay and immunohistochemistry (IHC). In
addition, four subpopulations from the luminal like ER+ PDX model were
subjected to molecular comparisons using whole genome expression profiling and
SNP array analysis of genomic aberrations.
Materials and Methods
Ethic statement
The MAS98.12 and MAS98.06 tumor models were established by implantation of
biopsy tissues from primary mammary carcinomas as previously described
(Approved by the Norwegian Regional Committee for Medical Research Ethics,
Health region II (reference number 2.2007.2155) [7, 16]. Informed written
consent was obtained from all patients.
All procedures and experiments involving animals were approved by the
National Animal Research Authority (http://www.fdu.no/), and were conducted
according to the regulations of the Federation of European Laboratory Animal
Science Association (FELASA). All surgery was performed under sevofluran
anaesthesia, and all efforts were made to minimize suffering.
Patient derived breast cancer xenografts models (PDX)
Both the primary carcinomas and the xenograft models have been characterized
using gene expression profiling. These analyses demonstrated that the primary
carcinomas could be classified as luminal-like and basal-like subtypes of breast
cancer, and that these molecular subtypes were retained in the MAS98.06 (ER+,
luminal-like) and MAS98.12 (ER-, basal-like) xenografts. Relevant characteristics
of the models are presented in [16]. Both models are now routinely serially
transplanted without enzymatic digestion, as 1-3mm3 pieces in nude (athymic)
mice. Notably, to optimize the conditions for tumorigenicity [17] the in vivo
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tumorigenicity assays using dissociated tumor cells in suspension were performed
using NOD/SCID interleukin-2 receptor gamma chain null (Il2rg-/-) (NSG) mice.
Mice were kept under pathogen-free conditions, at constant temperature
(21.5¡0.5 C˚) and humidity (55¡5%), 20 air changes/hr and a 12 hr light/dark
cycle. Distilled tap water was given ad libitum, supplemented with 17-b-estradiol
at a concentration of 4 mg/l. All mice used in the experiment were locally bred at
the animal facility of our institute.
Collection of primary tumor material
The five primary breast cancer samples analysed in this study were collected as
part of a study where patients were referred for surgical treatment of breast cancer
to several different hospitals in the Oslo region. The study was approved by the
Norwegian Regional Committee for Medical Research Ethics, Health region II
(reference number S-07278a). All patients have given written consent for the use
of material for research purposes.
Dissociation of tumors to single cell suspension for FACS.
Tumors, routinely implanted as 1–2 mm3 pieces, bilaterally in mammary fat pads
of female athymic nude mice (Athymic Nude-Foxn1nu; weight, 23–25 g; age, 12–
13 weeks), were harvested when largest tumor diameter reached 10 mm. Tumors
were then manually minced and incubated in Collagenase III solution
(Collagenase III, Worthington, Lakewood Township, USA (900U/ml), dissolved
in DMEM/F12 with 0,5% human serum albumin, 2% Hepes, Pencillin and
Streptamycin), for 3 hours at 37 C˚ on an orbital shaker. The digested tumor cells
were washed twice in DMEM/F12 medium following a quick spin after the second
wash, to precipitate and separate the organoid fraction from the single cell
suspension. Following an additional spinning of the single cell suspension, the
single cells were either frozen in 90% FCS with 10% DMSO or directly re-
suspended in flow blocking buffer for subsequent staining with antibodies and
further flow analysis or FACS.
Fluorescence-activated cell sorting and Flow analysis
Single cell suspensions were diluted in cold staining buffer (PBS containing 0.5%
FCS and 3% human immune globulin (Gammaguard) (N.V Baxter S.A,
Belgium)) and stained with fluorescently-labelled antibodies, diluted according to
the manufacturer’s recommendation. Following 30 min incubation at 4 C˚, the
stained cells were washed once with PBS, then re-suspended in PBS with 2% FCS
and further analysed by LSRII flow cytometer (Becton Dickinson) using BD
FACSDivaTM software. The antibody- stained single cell suspensions, sorted for
further re-injection or DNA/RNA extraction were, after the washing step, re-
suspended in DMEM/F12 with 0.5% human serum albumin, 2% Hepes, Penicillin
and Streptomycin. The cell populations were sorted by FACS DIVA flow
cytometer (Becton Dickinson), equipped with a 488nm Argon laser (Coherent)
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and 633nm HeNe laser (Spectra Physics), distributing cells from each population
into a separate tube containing DMEM/F12 with 0.5% human serum albumin,
2% Hepes, Penicillin and Streptomycin. The single cell suspensions were always
stained with 1 mg/ml propidium iodide (PI) (Sigma) prior to flow analysis or
sorting to exclude the dead cells from the analysis. Fluorescently-conjugated IgG
isotype controls (BD Biosciences, Franklin Lakes, USA) and/or unstained controls
were used to set the gates. A minimum of 10,000 events from the viable cell
population were recorded for each sample. FlowJo 7.6 software was used to
analyse the data. Sorted populations were defined as indicated on figures.
Antibodies
The following antibodies were used for FACS and flow analysis of human tumor
cells; anti-CD24-FITC (clone ML5), anti-CD15 (also known as SSEA-1clone
W6D3), anti-CD45-FITC (clone HI30), anti-EpCAM-APC (clone 9C4), were all
from Biolegend, San Diego, US. Anti-SSEA-4-PE (clone MC813-70), anti-H2kD-
FITC (clone SF1-1.1), anti-CD325-PE (also known as N-cadherin clone 8C11),
anti-CD44-PerCP-Cy5.5 (clone G-44-26, also known as G26), anti-CD29
(integrin b1, clone 18/CD29), anti-CD184-PE (clone 12G5), anti-CD49B-PE
(clone 12F1), anti-CD31-PE (clone WM59), anti-CD166-PE (clone 3A6), anti
CD271-PE (also known as p75, clone C40-1457), anti-anti-NG2-FITC (also
known as CSPG4, clone 9.2.27), anti-CD90-PE (clone 5E10), anti-CD-34-PE
(clone 581), anti-CD117-APC (also known as c-Kit, clone YB5.B8), anti-CD142-
PE (clone HTF1) and Annexin V-PE, were all from BD Biosciences, New Jersey,
US. Anti-CDV66-PE (clone SF10) and anti-Tra-1-85-PE were both from R&D
Systems, Oxon, UK. Anti-CD133/2-PE (clone 293-C3) was from Milteny Biotech,
Lund, Sweden.
For immunohistochemistry the following antibodies were used; anti-S100A4
(clone 20.1) [18], anti-ALDH1A1, rabbit polyclonal (cat no ab51028), Abcam,
Cambridge, UK, anti-CK19 (clone A-53-B/A2), Abcam, anti-CK-14 (clone
LL002), Novacostra Labs. Ltd., Newcastle Upon Tyne, UK, anti-CD49f (clone
GoH3), BD Biosciences, anti-Ki-67 (clone Ki-67), anti CD44 (clone DF1485) and
anti-EpCAM (clone Moc-31), DAKO, Copenhagen, Denmark,
Immunohistochemistry
Immunohistochemistry was performed using the Dako EnVisionTM + System,
Peroxidase (DAB) (K4011, Dako, Glostrup, DenmarK) and Dakoautostainer, or
VECTOR M.O.M.TM immunodetection Kit (PK-2200, Vector Laboratories).
Sections were deparaffinized and epitopes unmasked using PT-Link (Dako) and
EnVision Flex target retrieval solution, high pH or low pH, and then treated with
0.03% hydrogen peroxide (H2O2) for 5 minutes to block endogenous peroxidase.
After incubation with rabbit polyclonal antibody for 30 minutes at room
temperature, the sections were incubated with peroxidase labelled polymer
conjugated to goat anti-rabbit for 30 minutes. Tissue was stained for 10 minutes
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with 393-diaminobenzidine tetrahydrochloride (DAB) and then counterstained
with haematoxylin, dehydrated, and mounted in Diatex. Negative controls
included substitution of the polyclonal primary antibody with antibody diluent.
The specimens were given a sequential incubation with mouse Ig blocking
reagent (60 minutes) and working solution of diluent (5 minutes). Excess
working solution of diluent was blotted from the slides before incubation with
mouse monoclonal antibodies for 30 minutes. The sections were then incubated
with biotinylated anti-mouse IgG for 10 minutes and ABC reagents for 5 minutes.
Tissue was stained for 10 minutes with DAB and then counterstained with
haematoxylin, dehydrated, and mounted in Diatex. Negative controls included
substitution of the monoclonal antibody with mouse myeloma protein of the
same subclass and concentration as the monoclonal antibody.
In vivo tumorigenicity assay
EpCAM positive cells isolated by FACS were pelleted by centrifugation,
resuspended in 100 ml of PBS and re-counted. Non-viable cells were detected with
tryphan blue staining and excluded from the calculations. To test the stringency of
the trypan blue staining, aliquots of the subpopulations were subjected to live
(calcein AM) and dead dye (propidium iodide), staining and inspected for
differences in cell viability using a fluorescent microscope. In addition, Annexin V
flow cytometry was performed on the EpCAM positive population. Only the outer
perimeter of each population was isolated by FACS, ensuring maximum difference
in marker expression levels. The purity of the subpopulations was tested by
reanalyzing the sorted fractions by flow cytometry. Each fraction, dissolved in
100 ml PBS, containing 40.000 cells of 98% purity, was injected in the right
mammary fat pad of NSG mice. Tumor diameter was measured twice a week, and
the experiment was terminated when the diameter reached 12 mm.
Isolation of RNA and cDNA synthesis for qPCR
All RNA extractions were performed using Trizol Reagent manufacturer’s
instructions (Invitrogen Life Science, Carlsbad, USA). RNA concentration was
routinely assessed on the NanoDrop 1000 instrument (Thermo Fisher Scientific,
Waltham, USA). Generally 0.08–1 mg of RNA was reverse transcribed using the
qScript cDNA synthesis kit (Quanta BioSciences Inc.) in a volume of 20 ml and
then diluted (in dH2O) to 5–10 mg/ml.
Gene expression analysis
Four subpopulations from the luminal MAS9806 xenograft were sorted by FACS
based on the presence of EpCAM, SSEA-4 and CD24 cell surface markers on the
epithelial MAS9806 cells. Total RNA was isolated from four biological replicates
of each population (totally 16 samples). 50–100 ng of total RNA was amplified
and labeled with cy3-CTP following Agilent Low Input Quick Amplification
Labeling Kit protocol for One-Color Microarray-Based Gene Expression Analysis.
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Hybridization was performed according to the manufacturer’s protocol (Agilent
One-Color Microarray-Based Gene Expression Analysis v6.0) using 1650 ng cy3-
labeled cRNA per sample and hybridized onto Whole Human Genome Oligo
Microarrays (4x44K, G4112F).
The microarrays were scanned using Agilent Technologies Microarray Scanner
(G2505C). Data were extracted from the scanned images using Feature Extraction
Software (Agilent Technologies), version 10.7 and protocol GE1-107-Sep09 for
mRNA, using default settings and FULL text output. One sample from the double
positive cell fraction was removed from the further analysis due to poor data
quality. Raw data were uploaded to Gene expression omnibus (GEO) accession
number GSE48384.
Data analysis and statistics
Microarray expression data were filtered for spot quality and quantile normalized
using GeneSpring GX Software (Agilent). A final dataset was generated by
additionally averaging the signal intensity of multiple unique probes for each
gene. This set included data for 24210 unique genes on 15 microarrays from the
four cell subpopulations. Qlucore Omics Explorer 2.3 software was used to
compare gene expression profiles between different cell subpopulations. A student
t-test was performed to identify genes significantly differentially expressed
between the non-tumorigenic dbl.high subpopulation and the three tumorigenic
subpopulations. Only genes that contributed the most to the variation across the
dataset were included in the analysis. Filtering genes by variance (v50.2 for t-test)
excluded genes having variance lower than v compared to the gene having the
largest variance, from the analysis. The calculated P-values were adjusted for
multiple testing by applying a False Discovery Rate adjustment (FDR50.2). Gene
expression-based Outcome for Breast cancer Online (GOBO) tool was used for
prognostic validation of sets of genes in a pooled breast cancer data set comprising
1881-samples [19]. Association with outcome for the 26 gene set was investigated
by Kaplan-Meier analysis using overall survival and distant metastasis-free
survival as endpoint and 10-years censoring.
Validation of microarray data by RT-qPCR:
Real-time quantitative PCR reactions were performed on the iCycler instrument
from BioRad (Hercules, CA). All reactions were run in parallel, and all samples
were in 25 ml volume. Each primer mix contained 200 nM FAM-labeled probe,
300 nM of each primer and 16 Perfecta qPCR Supermix (Quanta BioSciences
Inc, Gaithersburg, MD). Expression of YARS, a t-RNA synthetase, was used for
sample validation and normalization of expression. The reference genes (YARS
and TBP) had been tested in a panel of cell lines and found to have equal
expression per ng of cDNA. All primers have been validated using appropriate
controls, and negative and positive controls for all targets were always included in
the PCR runs. Primers were designed using the probe finder software available
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online at the Universal ProbeLibrary assay design Center
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp), and all probes
are from the UniversalProbe Library collection (both Roche Applied Science).
Analysis of genomic copy number alterations
To compare genome wide copy number aberration patterns and degree of
heterogeneity between and within the four subpopulations, the luminal MAS9806
xenograft was sorted by FACS based on the presence of EpCAM, SSEA4 and CD24
cell surface markers on the epithelial cells. Genomic DNA was isolated using
Quiagen kit according to the manufacturer’s protocol, and subjected to Illumina
HumanOmniExpressExome v1.2 BeadChips (Performed by Aros Applied
Biotechnology A/S, Denmark). aData were analysed using GenomeStudio 2011.1
Software, and by R version 3.0.2 (2013-09-25), using the ‘‘DNAcopy package’’ for
segmentation. The standard Illumina reference file (HumanOmniExpressExome-
8v1-2_A.egt) was used to identify aberrations in relation to a normal genome. To
search for aberrations specific for each subpopulation, the four samples were also
compared pairvise. For each possible pairing of the four samples (6), a new
segmentation was applied in order to more easily see how much the samples
differed from each other (data not shown). Raw data were uploaded to Gene
Expression Omnibus (GEO) accession number GSE56103.
Results
EpCAM expression was a specific and sensitive marker for the
human cell population in both PDX models
After enzymatic degradation of PDX tissue the single cell suspensions contained a
mix of human and mouse cells. The initial challenge was to separate the human
cancer cells from the mouse stroma cells by flow cytometry. When staining with
the EpCAM antibody (clone 9C4), the flow analyses showed a defined
subpopulation in both xenografts (Figure 1A and B). It was, however, unclear
whether all the human cells (i.e. all cancer cells) in the cell suspension were
detected using EpCAM, and furthermore, whether the antibody also recognized
the mouse version of the antigen. The specificity and sensitivity of EpCAM as a
marker of human tumor cells, was tested by triple and quadruple staining
combining anti-EpCAM, anti-Tra-1-85 (pan anti-human antibody, filled blue),
anti-H2Kd (mouse MHC class I antibody, red line) and Hoecst-3342 (DNA-
content, grey contour), with subsequent flow cytometry analysis (Figure 1A and
B, right panel). Our results showed that the anti-EpCAM antibody was human
specific, and all the human cells in both xenografts were recognized as EpCAM
positive. Staining of the luminal xenograft suspension with the anti-mouse MHC
class I antibody and the pan anti-human antibody was mutually excluding
(Figure 1B right panel). The H2-kd antibody failed to show any binding in the cell
suspension from the basal-like tumor, while both Hoechst staining and Tra-1-85
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positivity confirmed the human origin of the EpCAM positive cells in both
xenografts (Figure 1A).
EpCAM positive tumor cells from the luminal-like xenograft were
tumorigenic
The two PDX models were routinely serially passed as 1-2 mm3 pieces implanted
orthotopically. The small tumor tissue pieces contain human tumor initiating cell
(TIC) population(s), as well as mouse stromal cells. For isolation and functional
Figure 1. Flow cytometry analysis of total cell fractions of dissociated cells from PDX models. A) Basal-like xenograft cells. B) Luminal-like xenograft
cells. A and B displays pseudo-color dot plots (left panels) and histograms (right panels). Freshly harvested xenografts were minced and the whole cell
suspensions were washed and stained with monoclonal antibody towards EpCAM, TRA-1-85 (filled blue in histograms), H2-kd (red line in lower histogram)
and Hoecst-33342 (intensity measure for DNA content of cells, grey contours in both histograms. Left peak indicate mouse cells, right peak indicate human
cells). The population positive for both EpCAM and TRA-1-85, i.e the human tumor cells, are indicated with a circle in the dot plots. C) Flow cytometry
analysis of double stained samples (marker of interest and EpCAM/Tra-1-85) of the Luminal-like PDX model. Flow cytometry histograms show the
distribution of the markers indicated in the figure. Filled blue histogram represents EpCAM positive tumor cell population, and the EpCAM negative
population (mouse stroma cells) is indicated by the red line. Grey contour represent unstained control.
doi:10.1371/journal.pone.0113278.g001
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characterization of TIC subpopulations, it was necessary to test whether the tumor
cells maintained their tumorigenic capacity when injected as sorted single cell
suspensions without the support of stromal cells. It was also of value to confirm
that the EpCAM negative population did not contain TICs. Both EpCAM positive
and EpCAM negative cells were therefore isolated using FACS, and re-injected
(105 and 104 cells, in vivo tumorigenicity assay) in the mammary fat pad of NSG
mice. The EpCAM positive cells from the luminal xenograft demonstrated the
highest tumorigenic capacity, indicating presence of TICs (Table 1, and growth
curves in Figure S1). As expected, the EpCAM negative fraction (containing only
mouse stroma cells) did not initiate tumor growth. Stained cells run through the
FACS machine but not sorted (all events) were used as control. Interestingly,
unsorted basal-like cells gave rise to only one tumor from four separate injections
in mice suggesting that these tumor cells might be dependent on support from the
stroma cells to initiate tumor growth.
Having established EpCAM as a marker specifying human tumor cells from
these two PDX models, we hypothesized that this population was heterogeneous
and that it would be possible to identify cell surface markers for prospective
detection and isolation of tumor cells with different tumorigenic capacity. To this
end, dissociated single cells from both xenografts were stained with EpCAM in
combination with a number of markers (Table 2) and IHC analysis of sectioned
xenograft tumors was performed (Figure S2). Of all the tested markers, CD24,
SSEA-4, SSEA-1 (CD15) CXCR4, E-cadherin and CD44v6 were expressed on the
EpCAM positive population of the tumorigenic luminal-like xenograft cells, and
thus candidates for defining functionally different luminal tumor cell subpopu-
lations (Table 2). To test whether the candidate antibodies were specifically anti–
human, dissociated cells from the luminal-like xenograft were double-stained
using anti-EpCAM or anti-TRA-1-85 in combination with either of the markers of
interest (Figure 1C). This experiment revealed that expression of some of the
markers did not define subpopulations, as all human cells were recognized
(CD49b, CD31, CD166). CD44v6 expression was excluded due to variable
expression caused by the enzymatic digestion of the tumors [20]. SSEA-1 was
excluded due to expression also in the basal-like model (Table 2) in which
dissociated cells in suspension showed very low tumorigenicity. We therefore
hypothesized that SSEA-1 might not define a population with tumorigenic
Table 1. Test of Tumorigenicity of Cell Fractions from two Breast Cancer Xenograft Models.
Surface marker
EpCAM
positive
EpCAM
positive
EpCAM
negative
EpCAM
negative All events All events
1:1 mix EpCAMpos
EpCAMneg
No of cells injected 105 104 105 104 105 104 105
Basal-like 0/7 0/6 0/9 0/6 1/4 0/6 0/2
Luminal-like 7/9 0/3 0/8 0/3 3/7 0/3 3/6
Injection in MFP of NSG mice.
doi:10.1371/journal.pone.0113278.t001
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potential, and chose to proceed with SSEA-4 and CD24 to define subpopulations
within the EpCAM-positive fraction of luminal-like xenograft cells.
SSEA-4 and CD24 are expressed in patient biopsies and define
tumorigenic subpopulations in the luminal-like PDX
Expression of CD24 has been associated with breast cancer cells of low
tumorigenic capacity [10], and several studies demonstrate that expression of
CD24 can classify functionally distinct subpopulations of tumor cells. SSEA-4 is a
much less used marker in breast cancer research, but was previously identified as a
marker of the ductal zones containing normal stem cells of the breast [21, 22]. It
was therefore interesting to investigate whether these markers were co-expressed
also in tumors derived directly from patients. Fresh tumor material from five
randomly chosen breast cancer patients was disaggregated and triple stained with
anti-EpCAM, anti-CD24 and anti-SSEA-4 antibodies. The results (Figure 2A)
Table 2. Expression of Cell Surface Markers and Aldefluoractivity in EpCAM Positive Cells from Two Breast
Cancer Xenografts Models, measured by flow cytometry.
Luminal-like Basal-like
Marker
Expression on EpCAM
+ cells
Expression on EpCAM
+ cells
SSEA-4/stage specific antigen 4 ++ 0
CD24/heat stable antigen 24 ++ +++
CD184/CXCR-4 ++ ++
CD31/PeCAM-1 ++++ 0
CD166/ALCAM ++++ +
CD44v6, splice variant of CD44 + +
E-cadherin, cadherin-1, ++ +
CD44/receptor for hyaluronic acid 0 0*
P75, LNGFR, CD271, 0 +
ALDH, aldefluor activity +++ ++
CD49f/integrin alpha 6 0 +++
Annexin V 0 0
CD90/Thy-1 0 0
CD34/transmembrane sialomucin family 0 0
CD142/tissue factor 0 ++
NG2, CSPG4, HMW-MAA 0 +
CD49b/integrin alpha 2 ++++ 0
CD15, SSEA-1, Lewis 1 antigen ++ ++
CD45/leucocyte common antigen 0 0
CD117/c-kit/ 0 ++
CD133 0 +++
++++ 5 all EpCAM positive cells positive, +++5 40-90% were positive, ++5 5–39% were positive, + 5 less
than 5% positive cells, 0 5 no cells expressed marker. * 5 was highly positive when xenografts tumor was
digested with trypsin.
doi:10.1371/journal.pone.0113278.t002
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confirmed that all three markers were, to a varying degree, expressed on primary
breast cancer cells, thus, indicating inter-patient variations in cell surface marker
expression, even within the EpCAM positive population. Similar analysis of
another PDX model (Luminal-like, HBCX-3 [5]), as well as MCF-7 and T47D
cells (Figure 2B) confirmed CD24 and SSEA-4 expression in other ER+ breast
cancer PDX models and cell lines.
SSEA-4 and CD24 define tumor cell subpopulations with different
tumorigenic ability
As Figure 2B and 3A demonstrate, SSEA-4 and CD24 can be used to define four
subpopulations in luminal like EpCAM positive cells; SSEA-4low/CD24low
(dbl.low), SSEA-4high cells (SSEA-4high), SSEA-4high/CD24high (dbl.high) and
CD24high cells (CD24high). To test whether they had different capacity for in vivo
tumorigenicity, FACS was used to isolate pure fractions from each subpopulation,
and 40.000 cells from each subpopulation were injected in MFP of NSG mice.
Under these conditions, the dbl.high cells did not produce tumors in any of the
four experiments while the three other populations did (Figure 3B). The dbl.high
subpopulation thus seemed to contain a significantly lower number of TICs than
the other fractions. The luminal PDX model is dependent of estrogen for growth,
hence, tumor growth cease if estrogen is removed [8]. Immunohistochemical
staining for estrogen receptor (ER) positivity showed that both the primary tumor
and the PDX contain ER positive and negative tumor cells (Figure S3 upper
Figure 2. Flow cytometry analysis of EpCAM positive cells from human primary breast tumors, xenografts, and breast cancer cell lines. Freshly
harvested primary or xenograft tumor material was minced and digested and the whole cell suspension was stained with anti-EpCAM antibody combined
with anti-CD24 and anti-SSEA-4. A) Flow analysis of EpCAM positive cells from five randomly chosen primary breast cancer tumors. F indicate tumor
number, ER 5estrogen-, PR5 progesterone-, and Her2- receptor status are indicated under the corresponding dot plot. IDC indicates that primary tumor
was invasive ductal carcinoma. B) Flow analysis of EpCAM positive cells from three PDX models and two breast cancer cell lines. The dot plots illustrate the
distribution of CD24 and SSEA-4 expressing cells. Red dots are antibody stained cells; black dots represent unstained control.
doi:10.1371/journal.pone.0113278.g002
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panel). It was therefore of interest to test whether the dbl.high fraction was
depleted of ER positive cells, and thus unable to respond to the growth
stimulatory signals from estrogen. ER staining of sorted subpopulations showed
that they all contained ER positive cells, demonstrating that absence of ER in the
dbl.high subpopulation could not explain their low tumorigenic capacity (Figure
S3).
SSEA-4high cells were tumorigenic, but did not give rise to
CD24high cells.
The cancer stem cell hypothesis proposed that cancer stem cells should have the
ability to reproduce the original tumor mass. To elucidate the self renewal
capacity of the subpopulations, three tumors from the SSEA-4high and dbl.low
populations, and two tumors from the CD24high populations (generation P0)
were disaggregated and analyzed for expression of EpCAM, CD24 and SSEA-4
(Figure 3D). Tumors initiated from the dbl.low and CD24high populations were
similar to the original xenografts, expressing all three markers (Figure 3D bottom
panels compared to 3C). However, the tumors initiated from SSEA-4high cells (red
Figure 3. In vivo functional characterizations of four EpCAM positive tumor cell subpopulations, defined by CD24 and SSEA-4, from the luminal-
like PDX. A) Concept figure illustrating the workflow of the in vivo tumorigenicity assays. The FAC-sorted populations are indicated by color in the dot plot.
Red indicates SSEA-4hi, blue indicate dbl.high, green indicate CD24hi and black dots indicate dbl.low cells. B) Growth curves of tumors resulting from
injection of FAC-sorted pure populations. 46104 cells from each fraction were injected in the right mammary fat pad of NSG c null mice. Tumor diameter was
measured twice each week. C) Flow cytometry analysis of EpCAM positive cells from the ‘‘original’’ tumor. This is the same tumor as in A, but the
fluorochrome intensity is here illustrated by histograms, and unstained control cells are included. Harvested tumors were disaggregated and analyzed by
flow cytometry after staining with anti- EpCAM, CD24 and SSEA-4 –antibodies. Dark blue histograms indicate the stained samples; light blue contours
indicate the unstained control cells. D) Flow cytometry analysis of EpCAM positive cells from tumors in B. Representative histograms are shown.
doi:10.1371/journal.pone.0113278.g003
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dots in Figure 3A and red lines in Figure 3B) did not contain CD24high cells;
hence the SSEA-4high population seemed to harbor TICs that could not
recapitulate the original tumor (Figure 3D upper panel compared to 3C). Tissue
from tumors originating from all three subpopulations was, furthermore,
implanted in the MFP of NSG mice and they were all able to establish and grow
(generation P1, results not shown).
Whole Genome Expression profiling revealed a gene set
predicting longer overall survival in clinical samples
The four subpopulations showed phenotypical and functional differences, and we
next aimed to relate the tumorigenic potential to differences in transcriptional
profiles. Total RNA was isolated from the four FAC-sorted subpopulations
(dbl.low, SSEA-4high, dbl.high and CD24high), and analyzed using whole genome
expression arrays. Unsupervised clustering of the 1000 most variable genes
revealed high similarity between the four subpopulations. Considering that these
comparisons were performed between cells originating from the same tumor and
with relatively homogenous EpCAM expression (Figure 1), and with no previous
selection from in vitro cultivation, this might be expected. The main variance
across the populations was caused by genes highly expressed in the dbl.high
population. This corresponded well to the functional data. A two group
comparison using t-test (Figure 4A) revealed 44 differentially expressed
transcripts (p#0.004, FDR50.20), of which 6 genes were less expressed in the
dbl.high compared to the other populations (Figure 4A and Table 3). The online
database ‘‘Gene expression-Based Outcome for Breast Cancer’’ (GOBO) [19] was
used to test the association between the set of genes highly expressed in the non-
tumorigenic population with outcome for 1881 breast cancer patients. 26 genes
from the 44-list were both highly expressed in dbl.high cells and represented in the
GOBO database. In tumors, high expression of the 26 genes, correlated
significantly with longer overall survival (OS) (N5737, p,0.0001) and distant
metastasis free survival (DMFS) (N51379, p,0.0001) in Kaplan-Meier analysis
(Figure 4B). The 26 gene set, furthermore, correlated with longer DMFS in
multiple subgroups of the 1881 sample breast cancer dataset; in basal-like, ER-
negative, LN-negative, as well as in grade 2 tumors, high expression of the 26
genes predicted lower risk of recurrent disease and longer DMFS. RT-qPCR
validation confirmed the stringency of the FACS procedure and microarray gene
expression analysis. This was exemplified by the CD24 gene which was found
highly expressed in the CD24 expressing populations, both by microarray analysis
and by RT-qPCR (Figure 4C).
Genomic aberrations could not explain the non-tumorigenic
phenotype.
The functional differences between the four subpopulations made it interesting to
screen for associated genomic aberrations utilizing SNP arrays. All four
Intratumoral Heterogeneity in Luminal-Like Breast Cancer
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subpopulations displayed similar copy number aberrations characteristics for the
luminal B breast cancer subtype. These genetic alterations included focal
amplification of 8p11-12, 11q13 (CCND1), 12q15 (MDM2) and multiple focal
amplicons distal to ERBB2 on chromosome 17q (Figure 5). Cell surface
expression of CD24 seemed to divide the EpCAM positive cells in two slightly
different variants with respect to copy number variations. The B allelic frequency
(BAF) plot of chromosome 2 was similar in the CD24 expressing populations and
Figure 4. Whole genome expression analyses of sorted tumor cell subpopulations. EpCAM positive cells from the luminal xenografts were
separated based on expression of SSEA-4 and CD24 using FACS. A) Normalized gene expression data from all 15 samples were subjected to t-test
comparison of two groups (dbl.high subopoulations vs. the tumorigenic subpopulations) with p#0.004 and FDR50.2. The figure shows a cluster heatmap of
the 44 significantly differentially expressed genes. Probes in yellow frames are not included in B, either because they are not annotated, the genes could not
be found in GOBO, or they showed lower expression in the dbl.high population. The A_32_P188263 probe maps to the C1QB gene, which is already
represented in the 26 gene list. B) Kaplan-Meier analysis using overall survival (OS) and distant metastasis free survival (DMFS) as endpoint and 10-year
censoring as displayed in GOBO. C) Total RNA was isolated from FAC-sorted subpopulations and RT-qPCR was performed using primers against CD24.
The bars illustrate the fold difference.
doi:10.1371/journal.pone.0113278.g004
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Table 3. List of the 44 probes and corresponding genes significantly differentially expressed in the non-tumorigenic population compared to the tumorigenic
populations.
ProbeID, highly expressed, used in GOBO Gene Symbol Gene name
A_23_P18713 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2
A_23_P258190 AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase)
A_23_P164650 APOE hypothetical LOC100129500; apolipoprotein E
*A_23_P113762 S100B S100 calcium binding protein B
*A_23_P113811 RPL19 ribosomal protein L19; ribosomal protein L19 pseudogene 12
*A_23_P146981 CTSZ cathepsin Z
*A_23_P204541 CNTN1 contactin 1
*A_24_P161173 PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog,
Drosophila)
*A_24_P664891 COX6A1 cytochrome c oxidase subunit VIa polypeptide 1
*A_24_P910246 TCN2 transcobalamin II; macrocytic anemia
*A_24_P924752 LGALS2 lectin, galactoside-binding, soluble, 2
*A_24_P935203 UBC ubiquitin C
A_23_P213385 BASP1 brain abundant, membrane attached signal protein 1
A_23_P137366 C1QB complement component 1, q subcomponent, B chain
A_24_P264943 COMP cartilage oligomeric matrix protein
A_23_P52556 CTSD cathepsin D
A_23_P202071 CUGBP2 CUGBP, Elav-Like Family Member, CELF2
A_23_P213745 CXCL14 chemokine (C-X-C motif) ligand 14
A_23_P119362 EMP3 epithelial membrane protein 3
A_23_P131183 GBX2 gastrulation brain homeobox 2
A_24_P402690 ITM2C integral membrane protein 2C
A_24_P42264 LYZ lysozyme (renal amyloidosis)
A_23_P401106 PDE2A phosphodiesterase 2A, cGMP-stimulated
A_23_P100711 PMP22 peripheral myelin protein 22
A_23_P75786 SLC15A3 solute carrier family 15, member 3
A_24_P367454 ZEB2 zinc finger E-box binding homeobox 2
Probe ID, less expressed in dbl.high compared to the tumorigenic populations
*A_32_P44099 GUCY1A2 guanylate cyclase 1, soluble, alpha 2
*A_32_P185530 RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5
*A_32_P158053 UBA6 ubiquitin-like modifier activating enzyme 6
*A_24_P196859 STS steroid sulfatase (microsomal), isozyme S
*A_32_P38268 BAT2L PRRC2B (proline-rich coiled-coil 2B)
A_23_P167920 DLL1 delta-like 1 (Drosophila)
Probe ID, not found in GOBO
A_23_P424603 C12orf53 chromosome 12 open reading frame 53
A_23_P372368 C21orf87 chromosome 21 open reading frame 87
A_23_P127565 LAYN layilin
A_23_P88222 PLD4 phospholipase D family, member 4
*A_32_P188263 C1QB complement component 1, q subcomponent, B chain
A_23_P132856 LRRC33 leucine rich repeat containing 33
A_23_P150547 PGA3 similar to Pepsin A precursor; pepsinogen 3, group I (pepsinogen A); pepsinogen 4,
group I (pepsinogen A)
*A_24_P910471 ACAA1A acetyl-CoA acyltransferase 1
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differed from CD24 negative populations (Figure 5 A and C compared to B and
D). Furthermore, on chromosome 18, distinct differences in BAF were evident
(Figure 5E-H). Importantly, none of the observed differences in genomic
aberrations were unique for the non-tumorigenic population (Figure 5E, G and
H). This indicates that although the cell surface marker based FAC-sorting
enriched for functional differences between the populations, underlying genomic
differences were not determinants of the observed in vivo tumorigenicity.
Discussion
Intratumoral heterogeneity may explain why systemic cancer therapies fail, and
many attempts have been made to study, especially genomic, heterogeneity in
patient samples [23, 24]. Studies of non-genetic molecular variations and
correlations with tumorigenic abilities (functional heterogeneity) are, due to
limited supply of material, literally impossible to perform in clinical samples. The
intratumor heterogeneity of a representative PDX model was therefore explored.
Clinically relevant cell surface markers were used to prospectively define four
subpopulations, and in vivo functional heterogeneity was measured. Finally,
transcriptional and genomic characteristics were analysed with emphasis on
differences between the populations that could potentially explain their divergent
in vivo tumorigenicity.
The in vivo assays were performed as four separate biological parallels, and the
purity and viability of the fractions were controlled before each injection. Even
though the common genetic origin of the four populations was confirmed by the
copy number analyses, no tumors were formed after any of the injections of the
dbl.high (CD24high/SSEA4high) fractions suggesting that this cell population had a
lower intrinsic tumorigenic potential than the others. Interestingly, tumors
resulting from injections of pure dbl.low - and pure CD24high cells were, when re-
analyzed by flow, always similar to the original PDX tumor. In other words, cells
expressing neither of the cell surface markers, or only CD24, had the ability to
form offspring containing all four subpopulations, and did so every time.
Conversely, cells expressing only the SSEA-4 marker, although tumorigenic, were
Table 3. Cont.
ProbeID, highly expressed, used in GOBO Gene Symbol Gene name
Probe ID, no annotation found
A_23_P205500
A_24_P15877
A_24_P324588
A_24_P640045
The 26 top genes were subjected to gene set analysis on breast cancer patient outcome in the GOBO database [19].
Probes downregulated in dbl.high.
Probes upregulated in dbl.high. The top 26 gene IDs were put in gene set analysis on tumors in the GOBO breast cancer gene expression database.
*Genes annotated by BLAST of probe sequence.
doi:10.1371/journal.pone.0113278.t003
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Figure 5. SNP array data displayed as unsegmented dotplots. Total signal intensity (LogR) and the B allele frequency (BAF) from all four subpopulations
are shown (A–D). For illustration of similarities and differences in genomic aberrations, overlay images comparing LogR and BAF from each population to
the dbl.high population are shown (E–H). Light blue color indicates copy number pattern observed only in dbl.high population, red color indicates pattern
observed only in the cell populations to which dbl.high is compared, and black indicates identical LogR and BAF.
doi:10.1371/journal.pone.0113278.g005
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never able to regenerate all four subpopulations in the resulting tumors.
Altogether, these results indicate that the TICs in the SSEA-4high population were
different from the TICs in dbl.low and CD24high populations. We therefore
hypothesize that tumor initiating cells from this PDX had more than one
phenotype, and the TICs within each subpopulation did not vary from
experiment to experiment. In line with this, it has been shown that from the same
cell line, both phenotypically pure luminal-like cells as well as their more stem
cell-like counterparts could give rise to tumors [25, 26]. This PDX model, always
regenerates the four defined subpopulations of the original PDX when routinely
implanted as small tumor tissue pieces in MFP, and the morphological
characteristics, receptor status and transcriptional profile are stable over multiple
passages [7]. Therefore, the SSEA-4high population does probably not dominate
over the dbl.low or CD24high population; otherwise, the CD24 expression would,
over time, be lost. Considering that SSEA-4 is regarded as a stem cell marker, this
result was unexpected. One possible explanation might be that CD24 expression
was redundant for developing new tumors from the SSEA-4high cells, or that the
daughter cells had lost their ability to differentiate along the luminal-epithelial
lineage, and hence did not express CD24. It is tempting to speculate that cells
expressing SSEA-4 could be locked into myoepithelial differentiation.
From the tumorigenicity assays and re-analysis of the resulting tumors, it was
clear that the four subpopulations represented three different functional
phenotypes; the non-tumorigeic, the PDX recapitulating, and the tumorigenic but
non-CD24 recapitulating. In search for transcriptional patterns explaining the
functional phenotypes, whole genome expression analysis was performed.
Corresponding well with the in vivo data, the dbl.high cell population was the
population that seemed to be most different from the others. Collectively, the
genes differentially expressed in this population compared to the other cell
populations, do not point to a specific tumor inhibiting function or cellular
target. It is therefore interesting that when using the genes highly expressed in the
non-tumorigenic population as a marker for patient stratification in the online
GOBO database, patients with high expression of this gene set experienced
improved overall survival and distant metastasis free survival in a multivariate
analysis. This finding is in concordance with our in vivo functional data, and
suggests that the genes highly expressed in the non-tumorigenic cells may affect
tumorigenicity when highly expressed in clinical samples. Although, high
expression of the 26 genes set in primary breast cancer cells seemed to indicate less
aggressive cancer, it does not necessarily indicate expression of the two cell surface
markers.
SNP arrays were employed to delineate whether copy number alterations were
specifically assigned to each population. Interestingly, genomic heterogeneity
within each population was revealed, indicating that the CD24 and SSEA-4 based
FAC-sorting did enrich for functional phenotypes, but perhaps not for underlying
genetic aberrations. It is possible that transcriptional differences between the TICs
within each subpopulation might be camouflaged by transcription from
intermixed less tumorigenic cells. It is also possible that the tumor initiating
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capacity might be better explained by differences in the post-transcriptional or
protein regulation mechanisms. The clinical impact of the genes highly expressed
in the dbl.high non-tumorigenic population may indicate that the observed
phenotypic and functional heterogeneity within this tumor most likely does not
result from genetic changes. Recently, Snuderl and colleagues [24] explored the
genetic intratumoral heterogeneity of glioblastomas. In a comment to their work
[27], different scenarios for interactions between cellular subclones within tumors
were discussed. Data presented here suggest that in this particular model, a so-
called ‘‘random’’ scenario, where subclones of cancer cells survive autonomously,
is the most probable. While one population could not give rise to new tumors,
three populations were tumorigenic, independently of each other, and
independently of stroma cells. Intriguingly, the three tumorigenic subpopulations,
also gave rise to two phenotypically different types of daughter tumors, implying
possible functional variations between the resulting tumors. This study
emphasizes the need for broad attacks against multiple subpopulations within the
primary tumor to obtain systemic eradication of the disease.
Supporting Information
Figure S1. Growth curves of tumors resulting from injection of 105 FAC-sorted
cells from the luminal-like PDX in the MFP of NSG mice. Upper chart: EpCAM
positive cells; out of nine injections, tumor was formed in seven. Middle chart:
2.56105 EpCAM positive cells were mixed with 2.56105 EpCAM negative cells
and injected. Of six injections, tumors formed in three. Lower chart: 105 cells run
through the FACS Diva, but not sorted, were injected. Of seven injections, three
tumors were formed.
doi:10.1371/journal.pone.0113278.S001 (TIF)
Figure S2. Expression of relevant markers in basal-like and luminal-like
orthotopically growing breast cancer xenografts models. A)
Immunohistochemistry (IHC) on sections from paraffin embedded tumors from
the basal-like (upper row) and luminal-like (lower row) PDX. The sections were
stained with antibodies to the proteins indicated. The antibodies shown did not
react with mouse stromal cells. B) Immunofluorecent staining of frozen tissue
sections from the two PDX models as indicated.
doi:10.1371/journal.pone.0113278.S002 (TIF)
Figure S3. Bright field images of immunohistochemical staining for estrogen
receptor in paraffin embedded sections from the original primary tumor (upper
left side), the luminal-like PDX model (upper right side), and stained cell
suspensions from each of the four subpopulations (Lower panel). The FAC-sorted
pure cell suspensions were placed on glass slides, fixed and stained. Cells showing
positive staining for ER are brown; the cell nuclei were counterstained with
hematoxylin (blue). Arrows point to ER positive cells.
doi:10.1371/journal.pone.0113278.S003 (TIF)
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